BioLargo (BLGO) issues 88,235 options to director for $15,000 fees

Rhea-AI Filing Summary

Jack B. Strommen, a director of BioLargo, Inc. (BLGO), received an option grant of 88,235 shares on 09/30/2025 under the company's 2024 Equity Incentive Plan. The option has an exercise price of $0.17 per share, is exercisable beginning 09/30/2025, and expires 09/30/2035. After this grant, Mr. Strommen directly beneficially owns 2,278,121 shares of common stock. The filing states the option was issued as payment for $15,000 of board fees for the most recently completed quarterly period. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and is reported as an individual filing by one reporting person.

Positive

• Option issuance documented: 88,235 options granted on 09/30/2025 under the 2024 Equity Incentive Plan
• Cash conservation: $15,000 in board fees paid via equity instead of cash (explicitly stated)

Negative

• None.

Insights

Compensation Analyst

Director received equity in lieu of cash fees: 88,235 options for $15,000 of board compensation.

The filing shows the company issued options under its 2024 Equity Incentive Plan to satisfy $15,000 in director fees, converting cash compensation into equity. This aligns director pay with shareholder outcomes by using a long-dated option (10-year term) with a $0.17 exercise price, which preserves cash for the company while creating potential future equity dilution if exercised.

Corporate Governance Expert

Routine insider reporting of a director grant; ownership disclosure updated.

The Form 4 updates beneficial ownership to 2,278,121 shares and documents the transaction date of 09/30/2025. The report was filed individually and executed by an attorney-in-fact, following disclosure requirements for Section 16 insiders. No additional transactions or departures are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

STROMMEN JACK B.

(Last) (First) (Middle)

7108 31ST AVENUE NORTH

(Street)

MINNEAPOLIS MN 55427

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.17	09/30/2025		A		88,235		09/30/2025	09/30/2035	Common Stock	88,235	(1)	2,278,121	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $15,000 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

	/s/ John R. Browning, attorney-in-fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BLGO director Jack B. Strommen receive on 09/30/2025?

He received an option to purchase 88,235 shares at an exercise price of $0.17, exercisable 09/30/2025 and expiring 09/30/2035.

Why was the option granted to the reporting person?

The option was issued as payment for $15,000 in board fees for the most recently completed quarterly period, under the Issuer's 2024 Equity Incentive Plan.

How many shares does Jack B. Strommen beneficially own after this transaction?

He beneficially owns 2,278,121 shares of BioLargo common stock following the reported transaction.

When was the Form 4 filed and who signed it?

The Form 4 reflects a transaction dated 09/30/2025 and the form was signed by an attorney-in-fact (John R. Browning) on 10/02/2025.

Was this Form 4 filed by a single reporting person or jointly?

It was filed by one reporting person as indicated on the form.